TTX Company Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • TTX Company's estimated annual revenue is currently $575.4M per year.(i)
  • TTX Company's estimated revenue per employee is $459,200

Employee Data

  • TTX Company has 1253 Employees.(i)
  • TTX Company grew their employee count by 7% last year.

TTX Company's People

NameTitleEmail/Phone
1
Chief Digital ArchitectReveal Email/Phone
2
Chief EngineerReveal Email/Phone
3
SVP Law & AdministrationReveal Email/Phone
4
VP EquipmentReveal Email/Phone
5
AVP MarketingReveal Email/Phone
6
AVP Supply ChainReveal Email/Phone
7
VP Law, General Counsel and Corporate SecretaryReveal Email/Phone
8
AVP Maintenance Planning & SchedulingReveal Email/Phone
9
AVP Digital Business DeliveryReveal Email/Phone
10
AVP Engineering and ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6M26-32%N/AN/A
#2
$19.2M655%N/AN/A
#3
$26.9M8258%N/AN/A
#4
$12.9M4929%N/AN/A
#5
$9.2M35-10%N/AN/A
#6
$225.1M5498%N/AN/A
#7
$8.9M3448%N/AN/A
#8
$12.6M484%N/AN/A
#9
$15.4M520%N/AN/A
#10
$16.5M568%N/AN/A
Add Company

What Is TTX Company?

TTX Company keeps the railroad industry in the US and Canada chugging along by leasing railcars. Rail companies generally prefer to rent railcars as needed rather than buy them because the cars are often switched and traded along the tracks. With 127,000 railcars, TTX's fleet includes three types of railcars (intermodal, autorack, and general use) designed to carry containers, autos, farm and construction equipment, and lumber and steel products. It has distribution centers in Illinois and Washington and maintains its fleet through three repair centers (in California, Florida, and South Carolina) and 31 inspection centers in the US. TTX is owned by the largest railroads in the US and Canada.

keywords:N/A

N/A

Total Funding

1253

Number of Employees

$575.4M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TTX Company News

2022-04-06 - Trishula Therapeutics Announces Promising Early Phase 1b Data of ...

Trishula is a privately held company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody, in collaboration with...

2022-04-06 - TransCode Therapeutics’ CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium

Two of the Company's other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively.

2022-03-22 - TransCode Therapeutics Reports 2021 Results; Provides Business ...

The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90%...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$474.8M12566%N/A
#2
$75M12565%N/A
#3
$478.9M126710%N/A
#4
$320.5M1272N/AN/A
#5
$102.5M12738%N/A